*Result*: Development and validation of the Tobacco Use Individual-level Simulation and Tracking (TwIST) Model.
Med Decis Making. 2018 Apr;38(3):400-422. (PMID: 29587047)
BMJ Open. 2016 Jun 09;6(6):e011045. (PMID: 27288378)
Prev Med. 2020 Feb 10;133:106019. (PMID: 32057958)
Nicotine Tob Res. 2025 Jan 22;27(2):179-191. (PMID: 38379278)
Tob Control. 2021 Dec;30(e2):e162-e168. (PMID: 32967986)
Tob Control. 2018 Mar;27(2):123-124. (PMID: 29475955)
Natl Vital Stat Rep. 2019 Jun;68(7):1-66. (PMID: 32501200)
Drug Alcohol Depend. 2019 Aug 1;201:85-93. (PMID: 31200279)
Tob Control. 2025 May 15;34(3):350-360. (PMID: 38937098)
JAMA Intern Med. 2020 Oct 1;180(10):1394-1398. (PMID: 32897288)
JAMA Netw Open. 2022 Feb 1;5(2):e2147891. (PMID: 35142830)
Nicotine Tob Res. 2021 May 24;23(6):966-975. (PMID: 33063826)
Tob Control. 2017 Jul;26(4):371-378. (PMID: 27507901)
Tob Control. 2023 Apr;32(e1):e31-e36. (PMID: 34230056)
CA Cancer J Clin. 2018 Mar;68(2):106-115. (PMID: 29384589)
PLoS One. 2013 Oct 25;8(10):e77941. (PMID: 24205038)
Tob Control. 2020 Jun 25;:. (PMID: 32587112)
Nicotine Tob Res. 2017 Nov 01;19(11):1257-1267. (PMID: 28339561)
N Engl J Med. 2013 Jan 24;368(4):351-64. (PMID: 23343064)
Nicotine Tob Res. 2024 Jan 22;26(2):194-202. (PMID: 37671638)
Am J Public Health. 2021 Dec;111(12):2167-2175. (PMID: 34878857)
Tob Control. 2020 Sep 29;:. (PMID: 32994297)
Med Clin North Am. 2004 Nov;88(6):1553-74, xi-xii. (PMID: 15464113)
Natl Vital Stat Rep. 2019 May;68(4):1-66. (PMID: 31112121)
Tob Induc Dis. 2011 May 23;9 Suppl 1:S7. (PMID: 21624153)
Natl Vital Stat Rep. 2020 Nov;69(12):1-45. (PMID: 33270553)
Nicotine Tob Res. 2020 Oct 8;22(10):1673-1675. (PMID: 33030210)
MMWR Morb Mortal Wkly Rep. 2023 May 05;72(18):475-483. (PMID: 37141154)
*Further Information*
*Simulation models of tobacco use behavior are useful analytic tools for projecting rates of tobacco use over time and identifying priority areas for intervention. This paper presents the Tobacco Use Individual-level Simulation and Tracking (TwIST) Model, an individual-based simulation model of tobacco use in the adult US population. We describe the model structure, data sources and parameters, and, in addition to future projections, compare modeled estimates of smoking prevalence to those from established surveys. The simulated population and model parameter estimates are informed by the Population Assessment of Tobacco and Health Study and other nationally representative datasets. To simulate tobacco use over time, we estimated 2nd order Markov models using multinomial logistic regression. To validate the model, we compared model estimates of tobacco use to data from three national surveys. The model estimates adult cigarette smoking rates will decline from a prevalence of 12.4% (95% uncertainty interval (95% UI): 12.2-12.8%) in 2020 to 9.6% (95% UI: 9.3-9.9%), 9.1% (95% UI: 8.9-9.4%), and 8.7% (95% UI: 8.5-9.0%) in 2030, 2040, and 2050, respectively. From 2020 through 2050, adults living in poverty are estimated to have a cigarette smoking rate 2.1-2.3 times higher than individuals living above the poverty line. The prevalence of menthol cigarette use will decline at a slower rate than the prevalence of non-menthol cigarette use (21% vs. 38% decline). Model projections of cigarette smoking prevalence typically fall within the 95% confidence intervals of prevalence estimates across three national surveys. Overall, the TwIST Model projects cigarette smoking prevalence rates that are similar to real-world estimates. If tobacco use continues based on current patterns, income-based disparities in smoking will persist and a growing proportion of individuals who smoke will use menthol cigarettes, which are known to be harder to quit.
(Copyright: © 2026 Mills et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)*
*I have read the journal’s policy and the authors of this manuscript have the following competing interests: KMR has served as a paid expert consultant representing plaintiffs in litigation against e-cigarette and tobacco companies.*